Symbols / CTMX Stock $2.98 +1.36% CytomX Therapeutics, Inc.

Healthcare • Biotechnology • United States • NMS
CTMX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Sean A. McCarthy DPHIL
Exch · Country NMS · United States
Market Cap 648.75M
Enterprise Value 304.90M
Income -62.14M
Sales 35.54M
FCF (ttm) -41.91M
Book/sh 1.47
Cash/sh 1.59
Employees 69
Insider 10d —
IPO Oct 08, 2015
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 18.17
Forward P/E -5.89
PEG —
P/S 18.25
P/B 2.03
P/C —
EV/EBITDA -5.03
EV/Sales 8.58
Quick Ratio 10.21
Current Ratio 10.38
Debt/Eq 0.89
LT Debt/Eq —
EPS (ttm) -0.53
EPS next Y -0.51
EPS Growth —
Revenue Growth -79.90%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-05-07
ROA -16.89%
ROE -34.28%
ROIC —
Gross Margin 100.00%
Oper. Margin -191.77%
Profit Margin -166.40%
Shs Outstand 217.70M
Shs Float 186.26M
Insider Own 0.56%
Instit Own 96.33%
Short Float 14.97%
Short Ratio 9.27
Short Interest 28.72M
52W High 8.21
vs 52W High -63.70%
52W Low 1.72
vs 52W Low 73.26%
Beta 2.09
Impl. Vol. 73.44%
Rel Volume 0.66
Avg Volume 6.98M
Volume 4.59M
Target (mean) $12.44
Tgt Median $12.00
Tgt Low $6.00
Tgt High $16.00
# Analysts 9
Recom Strong_buy
Prev Close $2.94
Price $2.98
Change 1.36%
About

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$12.44
Mean price target
2. Current target
$2.98
Latest analyst target
3. DCF / Fair value
$-3.46
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.98
Low
$6.00
High
$16.00
Mean
$12.44

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-11 main HC Wainwright & Co. Buy → Buy $11
2026-03-23 main Piper Sandler Overweight → Overweight $12
2026-03-19 main Barclays Overweight → Overweight $16
2026-03-18 main Jefferies Buy → Buy $16
2026-03-18 main Guggenheim Buy → Buy $15
2026-03-17 main Wedbush Outperform → Outperform $11
2026-03-16 main HC Wainwright & Co. Buy → Buy $17
2026-03-16 up JP Morgan Neutral → Overweight $12
2026-03-09 reit Guggenheim Buy → Buy $10
2026-02-04 main Cantor Fitzgerald Overweight → Overweight $10
2026-02-04 main Barclays Overweight → Overweight $10
2026-01-20 main Barclays Overweight → Overweight $8
2026-01-20 init Guggenheim — → Buy $10
2026-01-20 main Piper Sandler Overweight → Overweight $10
2025-11-11 main HC Wainwright & Co. Buy → Buy $10
2025-10-21 main Barclays Overweight → Overweight $6
2025-09-22 init Cantor Fitzgerald — → Overweight $6
2025-07-31 init Oppenheimer — → Outperform $7
2025-05-20 reit HC Wainwright & Co. Buy → Buy $5
2025-05-15 main Piper Sandler Overweight → Overweight $5
News
RSS: Latest CTMX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-17 MCCARTHY SEAN A. Chief Executive Officer — 118,969 $6.42 $764,138
2026-03-17 CHU YU-WAYE Officer — 21,279 $6.42 $136,675
2026-03-17 OGDEN CHRISTOPHER Chief Financial Officer — 19,323 $6.42 $124,112
2026-03-17 BELVIN MARCIA Officer — 31,492 $6.42 $202,273
2026-02-02 MCCARTHY SEAN A. Chief Executive Officer — 210,000 $0.00 $0
2026-02-02 CHU YU-WAYE Officer — 75,000 $0.00 $0
2026-02-02 OGDEN CHRISTOPHER Chief Financial Officer — 90,000 $0.00 $0
2026-02-02 BELVIN MARCIA Officer — 60,000 $0.00 $0
2026-02-02 LESTER RACHAEL Officer — 20,000 $0.00 $0
2025-11-06 MCCARTHY SEAN A. Chief Executive Officer — 101,793 $4.54 $461,906
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
76.20
-44.82%
138.10
+36.45%
101.21
+90.38%
53.16
Operating Revenue
76.20
-44.82%
138.10
+36.45%
101.21
+90.38%
53.16
Operating Expense
98.56
-12.86%
113.11
+5.02%
107.70
-30.29%
154.50
Research And Development
68.73
-17.57%
83.38
+7.34%
77.68
-30.42%
111.65
Selling General And Administration
29.84
+0.37%
29.73
-0.97%
30.02
-29.94%
42.85
General And Administrative Expense
29.84
+0.37%
29.73
-0.97%
30.02
-29.94%
42.85
Other Gand A
29.84
+0.37%
29.73
-0.97%
30.02
-29.94%
42.85
Total Expenses
98.56
-12.86%
113.11
+5.02%
107.70
-30.29%
154.50
Operating Income
-22.36
-189.47%
25.00
+485.49%
-6.48
+93.60%
-101.33
Total Operating Income As Reported
-22.36
-189.47%
25.00
+485.49%
-6.48
+93.60%
-101.33
EBITDA
-20.99
-178.42%
26.76
+721.10%
-4.31
+95.64%
-98.89
Normalized EBITDA
-20.99
-178.42%
26.76
+721.10%
-4.31
+95.64%
-98.89
Reconciled Depreciation
1.38
-22.17%
1.77
-18.71%
2.17
-10.97%
2.44
EBIT
-22.36
-189.47%
25.00
+485.49%
-6.48
+93.60%
-101.33
Net Income
-17.37
-154.50%
31.87
+5700.88%
-0.57
+99.43%
-99.32
Pretax Income
-17.13
-153.38%
32.09
+865.78%
3.32
+103.35%
-99.32
Net Non Operating Interest Income Expense
5.21
-27.05%
7.14
-27.46%
9.84
+486.23%
1.68
Net Interest Income
5.21
-27.05%
7.14
-27.46%
9.84
+486.23%
1.68
Interest Income Non Operating
5.21
-27.05%
7.14
-27.46%
9.84
+486.23%
1.68
Interest Income
5.21
-27.05%
7.14
-27.46%
9.84
+486.23%
1.68
Other Income Expense
0.03
+173.68%
-0.04
-26.67%
-0.03
-108.82%
0.34
Other Non Operating Income Expenses
0.03
+173.68%
-0.04
-26.67%
-0.03
-108.82%
0.34
Tax Provision
0.24
+6.25%
0.22
-94.24%
3.89
0.00
Tax Rate For Calcs
0.00
+2900.00%
0.00
-96.67%
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-17.37
-154.50%
31.87
+5700.88%
-0.57
+99.43%
-99.32
Net Income From Continuing Operation Net Minority Interest
-17.37
-154.50%
31.87
+5700.88%
-0.57
+99.43%
-99.32
Net Income From Continuing And Discontinued Operation
-17.37
-154.50%
31.87
+5700.88%
-0.57
+99.43%
-99.32
Net Income Continuous Operations
-17.37
-154.50%
31.87
+5700.88%
-0.57
+99.43%
-99.32
Normalized Income
-17.37
-154.50%
31.87
+5700.88%
-0.57
+99.43%
-99.32
Net Income Common Stockholders
-17.37
-154.50%
31.87
+5700.88%
-0.57
+99.43%
-99.32
Diluted EPS
-0.15
-139.47%
0.38
+3900.00%
-0.01
+99.34%
-1.51
Basic EPS
-0.15
-139.47%
0.38
+3900.00%
-0.01
+99.34%
-1.51
Basic Average Shares
137.94
+63.36%
84.44
+14.40%
73.81
+12.27%
65.74
Diluted Average Shares
137.94
+62.77%
84.75
+14.82%
73.81
+12.27%
65.74
Diluted NI Availto Com Stockholders
-17.37
-154.50%
31.87
+5700.88%
-0.57
+99.43%
-99.32
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
151.57
+25.75%
120.53
-40.27%
201.79
-22.65%
260.89
Current Assets
143.92
+34.12%
107.31
-41.34%
182.94
-22.85%
237.10
Cash Cash Equivalents And Short Term Investments
137.05
+36.20%
100.62
-42.34%
174.51
-9.88%
193.65
Cash And Cash Equivalents
12.67
-66.71%
38.05
+121.61%
17.17
-91.13%
193.65
Other Short Term Investments
124.39
+98.79%
62.57
-60.23%
157.34
0.00
Receivables
2.01
-35.13%
3.10
-9.59%
3.43
-90.46%
35.99
Accounts Receivable
2.01
-35.13%
3.10
-9.59%
3.43
-90.46%
35.99
Prepaid Assets
—
—
—
—
Other Current Assets
4.86
+35.68%
3.58
-28.35%
5.00
-33.10%
7.47
Total Non Current Assets
7.64
-42.21%
13.23
-29.85%
18.86
-20.74%
23.79
Net PPE
4.70
-55.67%
10.60
-34.46%
16.18
-23.04%
21.02
Gross PPE
21.62
-19.43%
26.83
-13.06%
30.87
-12.79%
35.39
Accumulated Depreciation
-16.92
-4.24%
-16.23
-10.51%
-14.69
-2.19%
-14.37
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
16.62
-0.44%
16.69
+2.44%
16.30
-4.14%
17.00
Construction In Progress
0.00
0.00
-100.00%
0.37
-47.80%
0.70
Other Properties
3.40
-58.26%
8.14
-33.42%
12.22
-23.38%
15.95
Leases
1.60
-20.00%
2.00
+1.11%
1.98
+13.83%
1.74
Goodwill And Other Intangible Assets
1.39
-9.46%
1.53
-8.70%
1.68
-8.00%
1.82
Goodwill
0.95
+0.00%
0.95
+0.00%
0.95
+0.00%
0.95
Other Intangible Assets
0.44
-24.87%
0.58
-20.03%
0.73
-16.69%
0.88
Other Non Current Assets
1.56
+42.54%
1.09
+9.30%
1.00
+5.93%
0.94
Total Liabilities Net Minority Interest
52.56
-56.56%
120.99
-51.46%
249.24
-28.10%
346.64
Current Liabilities
46.62
-45.65%
85.77
-44.99%
155.91
+2.17%
152.61
Payables And Accrued Expenses
15.50
+15.43%
13.43
-29.55%
19.06
-30.09%
27.26
Payables
1.30
+19.58%
1.09
-25.38%
1.46
-48.10%
2.81
Accounts Payable
1.30
+19.58%
1.09
-25.38%
1.46
-48.10%
2.81
Current Accrued Expenses
14.20
+15.07%
12.34
-29.89%
17.60
-28.02%
24.45
Current Debt And Capital Lease Obligation
4.24
-17.59%
5.14
+12.12%
4.59
+12.42%
4.08
Current Capital Lease Obligation
4.24
-17.59%
5.14
+12.12%
4.59
+12.42%
4.08
Current Deferred Liabilities
26.88
-60.01%
67.20
-49.19%
132.27
+9.07%
121.27
Current Deferred Revenue
26.88
-60.01%
67.20
-49.19%
132.27
+9.07%
121.27
Total Non Current Liabilities Net Minority Interest
5.94
-83.12%
35.22
-62.26%
93.33
-51.90%
194.03
Long Term Debt And Capital Lease Obligation
0.00
-100.00%
4.24
-54.82%
9.38
-32.84%
13.97
Long Term Capital Lease Obligation
0.00
-100.00%
4.24
-54.82%
9.38
-32.84%
13.97
Non Current Deferred Liabilities
1.59
-94.08%
26.86
-66.44%
80.05
-55.54%
180.06
Non Current Deferred Revenue
1.59
-94.08%
26.86
-66.44%
80.05
-55.54%
180.06
Other Non Current Liabilities
4.35
+5.78%
4.12
+5.70%
3.89
—
Stockholders Equity
99.01
+21812.28%
-0.46
+99.04%
-47.45
+44.67%
-85.75
Common Stock Equity
99.01
+21812.28%
-0.46
+99.04%
-47.45
+44.67%
-85.75
Capital Stock
0.00
+100.00%
0.00
+0.00%
0.00
+0.00%
0.00
Common Stock
0.00
+100.00%
0.00
+0.00%
0.00
+0.00%
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
170.19
+112.47%
80.10
+19.00%
67.31
+1.63%
66.23
Ordinary Shares Number
170.19
+112.47%
80.10
+19.00%
67.31
+1.63%
66.23
Additional Paid In Capital
810.84
+17.33%
691.10
+2.25%
675.90
+6.09%
637.12
Retained Earnings
-711.95
-2.95%
-691.58
+4.41%
-723.45
-0.08%
-722.88
Gains Losses Not Affecting Retained Earnings
0.11
+311.11%
0.03
-71.58%
0.10
+850.00%
0.01
Other Equity Adjustments
0.11
+311.11%
0.03
-71.58%
0.10
+850.00%
0.01
Total Equity Gross Minority Interest
99.01
+21812.28%
-0.46
+99.04%
-47.45
+44.67%
-85.75
Total Capitalization
99.01
+21812.28%
-0.46
+99.04%
-47.45
+44.67%
-85.75
Working Capital
97.31
+351.89%
21.53
-20.32%
27.02
-68.02%
84.49
Invested Capital
99.01
+21812.28%
-0.46
+99.04%
-47.45
+44.67%
-85.75
Total Debt
4.24
-54.82%
9.38
-32.84%
13.97
-22.61%
18.06
Capital Lease Obligations
4.24
-54.82%
9.38
-32.84%
13.97
-22.61%
18.06
Net Tangible Assets
97.62
+5010.51%
-1.99
+95.95%
-49.12
+43.91%
-87.58
Tangible Book Value
97.62
+5010.51%
-1.99
+95.95%
-49.12
+43.91%
-87.58
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-75.59
+12.34%
-86.23
-53.89%
-56.03
+49.42%
-110.79
Cash Flow From Continuing Operating Activities
-75.59
+12.34%
-86.23
-53.89%
-56.03
+49.42%
-110.79
Net Income From Continuing Operations
-17.37
-154.50%
31.87
+5700.88%
-0.57
+99.43%
-99.32
Depreciation Amortization Depletion
1.38
-22.17%
1.77
-18.71%
2.17
-10.97%
2.44
Depreciation
1.23
-24.17%
1.62
-20.06%
2.03
-11.67%
2.30
Amortization Cash Flow
0.15
+0.00%
0.15
+0.00%
0.15
+0.00%
0.15
Depreciation And Amortization
1.38
-22.17%
1.77
-18.71%
2.17
-10.97%
2.44
Amortization Of Intangibles
0.15
+0.00%
0.15
+0.00%
0.15
+0.00%
0.15
Other Non Cash Items
4.48
+9.77%
4.08
+9.52%
3.73
+9.26%
3.41
Stock Based Compensation
6.30
-17.81%
7.67
-10.40%
8.56
-34.80%
13.12
Asset Impairment Charge
0.40
+279.25%
0.11
0.00
-100.00%
0.25
Change In Working Capital
-68.58
+45.75%
-126.42
-102.23%
-62.51
-103.92%
-30.65
Change In Receivables
1.09
+231.31%
0.33
-98.99%
32.55
+192.49%
-35.20
Changes In Account Receivables
1.09
+231.31%
0.33
-98.99%
32.55
+192.49%
-35.20
Change In Prepaid Assets
-1.24
-186.67%
1.43
-40.66%
2.42
+175.92%
-3.18
Change In Payables And Accrued Expense
-2.83
+71.51%
-9.93
-17.22%
-8.47
+12.86%
-9.72
Change In Accrued Expense
-3.05
+68.33%
-9.63
-36.74%
-7.04
+28.04%
-9.78
Change In Payable
0.22
+174.41%
-0.30
+79.17%
-1.43
-2197.06%
0.07
Change In Account Payable
0.22
+174.41%
-0.30
+79.17%
-1.43
-2197.06%
0.07
Change In Other Working Capital
-65.60
+44.53%
-118.25
-32.85%
-89.01
-637.34%
16.57
Change In Other Current Assets
—
—
-0.06
-106.41%
0.87
Investing Cash Flow
-59.74
-159.92%
99.70
+166.17%
-150.67
-253.34%
98.26
Cash Flow From Continuing Investing Activities
-59.74
-159.92%
99.70
+166.17%
-150.67
-253.34%
98.26
Net PPE Purchase And Sale
-0.22
+29.03%
-0.31
+63.10%
-0.84
+51.72%
-1.74
Purchase Of PPE
-0.22
+29.03%
-0.31
+63.10%
-0.84
+51.72%
-1.74
Capital Expenditure
-0.22
+29.03%
-0.31
+63.10%
-0.84
+51.72%
-1.74
Net Investment Purchase And Sale
-59.52
-159.52%
100.01
+166.75%
-149.83
-249.83%
100.00
Purchase Of Investment
-192.52
-23.82%
-155.49
+63.40%
-424.83
0.00
Sale Of Investment
133.00
-47.95%
255.50
-7.09%
275.00
+175.00%
100.00
Financing Cash Flow
110.45
+1368.31%
7.52
-75.12%
30.23
+4565.12%
0.65
Cash Flow From Continuing Financing Activities
110.45
+1368.31%
7.52
-75.12%
30.23
+4565.12%
0.65
Net Common Stock Issuance
109.64
+1486.84%
6.91
—
0.00
Proceeds From Stock Option Exercised
0.81
+32.30%
0.61
-97.97%
30.23
+4565.12%
0.65
Changes In Cash
-24.89
-218.55%
20.99
+111.89%
-176.48
-1385.51%
-11.88
Beginning Cash Position
39.08
+116.05%
18.09
-90.70%
194.57
-5.75%
206.45
End Cash Position
14.19
-63.68%
39.08
+116.05%
18.09
-90.70%
194.57
Free Cash Flow
-75.81
+12.40%
-86.54
-52.16%
-56.88
+49.46%
-112.53
Income Tax Paid Supplemental Data
—
—
—
—
Amortization Of Securities
-2.21
+58.46%
-5.31
+28.41%
-7.42
-14167.31%
-0.05
Common Stock Issuance
109.64
+1486.84%
6.91
—
0.00
Issuance Of Capital Stock
109.64
+1486.84%
6.91
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category